Foamix CEO: IPO Was Successful Amid Volatile Stock

The transcript discusses the experience of a specialty pharma company after its successful IPO on NASDAQ. The company now has $45 million to advance its lead products into clinical trials and marketing. Despite market volatility, the company is focused on developing topical treatments for acne and other skin conditions, which require significant funding. Investors value the company based on its potential to capture a large portion of the acne treatment market, which is over $1 billion in the U.S. alone. The company aims to address unmet needs in dermatology with its innovative products.

What advantages does the company's topical antibiotic offer compared to traditional oral treatments?

What is the estimated market size for acne treatment in the United States?